Obesity, but Not Ethanol, Promotes Tumor Incidence and Progression in a Mouse Model of Hepatocellular Carcinoma in Vivo
Overview
General Surgery
Radiology
Affiliations
Background: Hepatocellular carcinoma (HCC) is a major global health burden. Although chronic, heavy alcohol abuse is an established risk factor for HCC, obesity is emerging as an increasingly important factor in HCC development. Given that other risk factors for HCC act synergistically to promote tumorigenesis, we investigated the effects of diet-induced obesity and chronic ethanol consumption on tumor progression.
Methods: A diethylnitrosamine (DEN) mouse model of HCC was established and mice randomized to control (CD; 10 % kcal% fat) or high fat (HFD; 60 % kcal% fat diet) at 5 weeks of age. At 35 weeks, mice were randomized to 10/20 % ethanol (EtOH) in drinking water (alternate days), or drinking water (H2O) alone. Tumor incidence/size were measured and confirmed. Liver tissue was analyzed for oxidative stress and EtOH-metabolizing enzymes and serum analyzed for liver function and nutritional status.
Results: DEN treatment induced HCC formation in 60 % CD-H2O mice (6 of 10), an effect exacerbated by HFD (89 %). Tumors in HFD animals occupied significantly more of the liver than mice on CD. EtOH-feeding did not impact HCC incidence or tumor size. HFD resulted in increased liver injury and liver:body weight ratio regardless of EtOH consumption. Increased tumor incidence was associated with elevated hepatic oxidative stress in the absence of changes in intrinsic antioxidant (glutathione) levels.
Conclusions: Obesity independently promoted HCC formation in the absence or presence of a known hepatocarcinogen (DEN), and enhanced both number and size of hepatic tumors independent of chronic EtOH consumption in mice.
Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Fu Y, Hua Y, Alam N, Liu E Nutrients. 2024; 16(18).
PMID: 39339720 PMC: 11435380. DOI: 10.3390/nu16183120.
Macrophages and the development and progression of non-alcoholic fatty liver disease.
Alabdulaali B, Al-Rashed F, Al-Onaizi M, Kandari A, Razafiarison J, Tonui D Front Immunol. 2023; 14:1195699.
PMID: 37377968 PMC: 10291618. DOI: 10.3389/fimmu.2023.1195699.
Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application.
Liu S, Huang F, Ru G, Wang Y, Zhang B, Chen X Front Oncol. 2022; 12:902820.
PMID: 35847898 PMC: 9279915. DOI: 10.3389/fonc.2022.902820.
Kincaid J, Weiss G, Hill-Baskin A, Schmidt H, Omoijuanfo O, Thompson C Obesity (Silver Spring). 2022; 30(7):1420-1429.
PMID: 35610936 PMC: 9256765. DOI: 10.1002/oby.23435.
Attal N, Sullivan M, Girardi C, Thompson K, McKillop I Transl Oncol. 2020; 14(1):100975.
PMID: 33290990 PMC: 7719965. DOI: 10.1016/j.tranon.2020.100975.